These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6568787)

  • 21. Preparation of human factor D of the alternative pathway of complement.
    Reid KB; Johnson DM; Gagnon J; Phohaska R
    Methods Enzymol; 1981; 80 Pt C():134-43. PubMed ID: 6918766
    [No Abstract]   [Full Text] [Related]  

  • 22. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
    Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
    J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The alternative complement pathway in bovine serum: the isolation of a serum protein with factor B activity.
    Pang AS; Aston WP
    Immunochemistry; 1978 Aug; 15(8):529-34. PubMed ID: 83291
    [No Abstract]   [Full Text] [Related]  

  • 27. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
    Baker PJ; Parker CJ; Osofsky SG
    Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages.
    Beuscher HU; Brade V
    Immunology; 1986 Aug; 58(4):545-51. PubMed ID: 3089917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation and characterization of rabbit properdin of the alternative complement pathway.
    Nakano Y; Matsuda T; Sakamoto T; Tomita M
    J Immunol Methods; 1986 Jun; 90(1):77-83. PubMed ID: 3635564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
    von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
    Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural biology of the alternative pathway convertase.
    Xu Y; Narayana SV; Volanakis JE
    Immunol Rev; 2001 Apr; 180():123-35. PubMed ID: 11414354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A monoclonal antibody which blocks the function of factor D of human complement.
    Pascual M; Catana E; Spertini F; Macon K; Volanakis JE; Schifferli JA
    J Immunol Methods; 1990 Mar; 127(2):263-9. PubMed ID: 2313104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity.
    Englberger W; Hadding U; Etschenberg E; Graf E; Leyck S; Winkelmann J; Parnham MJ
    Int J Immunopharmacol; 1988; 10(6):729-37. PubMed ID: 3198307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between the alternative complement pathway and proteases of the coagulation system.
    Kazatchkine MD; Jouvin MH
    Adv Exp Med Biol; 1984; 167():235-9. PubMed ID: 6561912
    [No Abstract]   [Full Text] [Related]  

  • 38. [A new low molecular-weight protein effector of human complement from the venom of the Central Asian cobra Naja naja oxiana].
    Kozlov LV; Soliakov LS; Zinchenko AA
    Bioorg Khim; 1984 Mar; 10(3):323-32. PubMed ID: 6567467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides.
    Lesavre P; Gaillard MH; Halbwachs-Mecarelli L
    Eur J Immunol; 1982 Mar; 12(3):252-4. PubMed ID: 6920299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Vogel CW; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.